The Indian Council of Medical Research (ICMR) on Thursday approved a novel RT-qPCR test kit by Chennai- based KRIYA Medical technologies that can detect influenza (H1N1, H3N2, Yamagata and Victoria sublineages), Covid-19, and respiratory syncytial virus (RSV).
The approval of the kit marketed as KRIVIDA Trivus comes even as several parts of the country are facing a signifi- cant rise in these viruses.
![](https://thelivenagpur.com/wp-content/uploads/2023/03/07E6AF8F-A49C-4477-808D-42D3B1280E97-1024x1024.jpeg)
The three pathogens have similar initial symptoms but differ in how the illness progresses, how easily they spread, and how they are treated.
The KRIVIDA Trivus effectively distin- guishes influenza, SARS-CoV-2 and res- piratory syncytial virus, within the shortest TAT (turnaround time), — cycle time of 27 minutes, and the time taken for the result to be read can vary between 50-60 minutes.
This can enable an immediate line of treatment, the company said in a statement.
The kit can also be used in all the avail- able RT-PCR equipment.
The ICMR evaluated the kit at National Institute of Virology, Pune, using 225 known positive samples and 85 nega- tive samples.
The overall sensitivity of KRIVIDA Trivus is 99.11 per cent and specificity is 100 per cent.